These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10528643)
1. Insulin-mediated sympathoexcitation in obesity and type 2 diabetes. Muntzel MS Nephrol Dial Transplant; 1999 Oct; 14(10):2282-5. PubMed ID: 10528643 [No Abstract] [Full Text] [Related]
2. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases. Balasubramanian P; Hall D; Subramanian M Geroscience; 2019 Feb; 41(1):13-24. PubMed ID: 30519806 [TBL] [Abstract][Full Text] [Related]
3. [How to prevent the incidence of hypertension in type 2 diabetes patients]. Murakami H; Shimamoto K Nihon Rinsho; 2003 Jul; 61(7):1154-60. PubMed ID: 12877077 [TBL] [Abstract][Full Text] [Related]
4. Insulin and blood pressure regulation. Gans RO; Donker AJ J Intern Med Suppl; 1991; 735():49-64. PubMed ID: 2043223 [TBL] [Abstract][Full Text] [Related]
5. [Insulin and arterial hypertension: role of hypersympathicotonia]. Oganov RG; Aleksandrov A Ter Arkh; 2002; 74(12):5-7. PubMed ID: 12577828 [No Abstract] [Full Text] [Related]
6. Insulin resistance and hypertension--implications for treatment. Rutherford PA; Thomas TH; Wilkinson R Postgrad Med J; 1991 Oct; 67(792):869-75. PubMed ID: 1758796 [No Abstract] [Full Text] [Related]
7. Insulin, the renin-angiotensin-aldosterone system and blood pressure. Tait JF; Tait SA Perspect Biol Med; 1997; 40(2):246-59. PubMed ID: 9058954 [No Abstract] [Full Text] [Related]
8. The renin-angiotensin system in the pathophysiology of type 2 diabetes. Goossens GH Obes Facts; 2012; 5(4):611-24. PubMed ID: 22986649 [TBL] [Abstract][Full Text] [Related]
9. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Masuo K; Lambert GW; Esler MD; Rakugi H; Ogihara T; Schlaich MP Hypertens Res; 2010 Jun; 33(6):521-8. PubMed ID: 20339374 [TBL] [Abstract][Full Text] [Related]
10. Metabolic domino: new concept in lifestyle medicine. Itoh H Drugs Today (Barc); 2006 Dec; 42 Suppl C():9-16. PubMed ID: 17245476 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of hypertension in patients with type 2 diabetes mellitus]. Hess K Dtsch Med Wochenschr; 2012 Nov; 137(48):2489-92. PubMed ID: 23114910 [No Abstract] [Full Text] [Related]
12. Sex Differences in Mechanisms of Hypertension Associated With Obesity. Faulkner JL; Belin de Chantemèle EJ Hypertension; 2018 Jan; 71(1):15-21. PubMed ID: 29133358 [No Abstract] [Full Text] [Related]
14. The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. Davies J; Struthers A J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):150-5. PubMed ID: 12563564 [TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of elevated blood pressure in obesity-related hypertension]. Aoi W Nihon Rinsho; 1992 May; 50 Suppl():420-5. PubMed ID: 1512980 [No Abstract] [Full Text] [Related]
16. Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes mellitus and obesity. Takahashi A; Tabuchi M; Suzuki W; Iizuka S; Nagata M; Ikeya Y; Takeda S; Shimada T; Aburada M Metabolism; 2006 Dec; 55(12):1664-9. PubMed ID: 17142141 [TBL] [Abstract][Full Text] [Related]
17. The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new? Palau V; Riera M; Soler MJ Endocrinol Diabetes Nutr; 2017 May; 64(5):237-240. PubMed ID: 28495318 [No Abstract] [Full Text] [Related]